Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodomethane SCHEMBL3898463 | 0.96 | MEN1 (0.53) | MEN1KMT2AHSD11B1OPRM1AKR1C1 | |
| SCHEMBL21761835 | 0.93 | MEN1 (0.54) | MEN1KMT2AHSD11B1OPRM1AKR1C1 | |
| SCHEMBL2481767 | 0.92 | AKR1C1 (0.58) | MEN1KMT2AHSD11B1OPRM1AKR1C1 | |
| SCHEMBL1041983 | 0.92 | AKR1C1 (0.63) | MEN1KMT2AHSD11B1AKR1C1HDAC4 | |
| SCHEMBL1042494 | 0.91 | HDAC4 (0.62) | MEN1KMT2AHSD11B1AKR1C1HDAC4 | |
| SCHEMBL1042365 | 0.91 | HDAC4 (0.62) | MEN1KMT2AHSD11B1AKR1C1HDAC4 | |
| SCHEMBL1038755 | 0.91 | HDAC4 (0.62) | MEN1KMT2AHSD11B1AKR1C1HDAC4 | |
| SCHEMBL1626631 | 0.88 | ALDH1A1 (0.61) | MEN1KMT2AHSD11B1APOBEC3AAPOBEC3G | |
| SCHEMBL5765569 | 0.88 | MEN1 (0.50) | MEN1KMT2AHSD11B1OPRM1AKR1C1 | |
| SCHEMBL378799 | 0.88 | OPRM1 (0.70) | MEN1KMT2AHSD11B1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3573972-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2026-01-14 | — | — | EP | disclosed |
| EP-3856734-B1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-12065422-B2 | Reagents and process for direct C—H functionalization | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| EP-4408416-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2024-08-07 | — | — | EP | disclosed |
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118139868-A | Orally bioavailable nucleoside analogs | 维纳拓尔斯制药公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118043044-A | Allosteric ketene inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-1145609-C | Piperazine compounds and medical use thereof | ������ҩ��ʽ���� | 2004-04-14 | — | — | CN | disclosed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003074050-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-12 | — | — | WO | disclosed |
| US-20030055064-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-03-20 | — | — | US | disclosed |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-01-23 | — | — | US | disclosed |
| US-6455528-B1 | TUMOR NECROSIS FACTOR ANTAGONIST AND/OR INTERLEUKIN PROMOTER; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE TREATMENT | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| CN-1281438-A | Piperazine compounds and their use as pharmaceuticals | EFUKU CO LTD (JP) | 2001-01-24 | — | — | CN | disclosed |
| EP-1029851-A1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999015524-A1 | THIAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055064-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | MEN1 4747/4885KMT2A 2109/4885HSD11B1 1730/4885 |
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | MEN1 1313/4885KMT2A 4426/4885HSD11B1 231/4885 |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | MEN1 4758/4885KMT2A 2049/4885HSD11B1 1827/4885 |
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | MEN1 4571/4885KMT2A 2302/4885HSD11B1 278/4885 |
| US-12065422-B2 | Reagents and process for direct C—H functionalization | CFH, DOHH, CTSH | MEN1 2686/4885KMT2A 934/4885HSD11B1 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.